• Sino Biopharm licenses TQC3721 inhaled PDE3/4 inhibitor to AstraZeneca, licenses Trelegy Ellipta and Anoro Ellipta from GSK

  According to Sino Biopharmaceutical, AstraZeneca will pay $200 million up front and a total of up to $1.9 billion for the development, manufacturing, and commercialization rights to Sino Biopharm’s TQC3721 inhaled PDE3/4 inhibitor outside of… [Read more . . .]

• ARS Pharma names Donn Casale as its new CEO

  ARS Pharmaceuticals, whose only product is neffy epinephrine nasal spray, announced that long-time CEO Richard Lowenthal has left the company and that Donn Casale, has taken over as CEO and Director. Casale joined ARS Pharma… [Read more . . .]

• Nebu-Flow joins Innovate UK Scaleup Programme

  Nebulizer developer Nebu-Flow, which recently received a £2 million Scottish Enterprise grant, announced that it has been invited to join the Innovate UK Scaleup Programme, which will provide access to a “virtual executive team.” The… [Read more . . .]

• Atisama and Monash University get AU $15 million for continued development of RB042 inhaled SSO therapy

  The Australian Medical Research Future Fund (MRFF) Frontier Health and Medical Research Initiative is providing over AU $15 million to Atisama Therapeutics (formerly Rage Bio) and Monash University to support continued development of RB042 inhaled… [Read more . . .]

• Vistagen says Phase 3 PALISADE-4 study of fasedienol nasal spray for social anxiety disorder failed to meet its primary endpoint

  Vistagen has announced that the Phase 3 PALISADE-4 public speaking challenge study of intranasal fasedienol (PH94B) for the treatment of social anxiety disorder failed to meet its primary endpoint. In December 2025, the company announced… [Read more . . .]

• Insmed names Samuele Butera as Senior VP, General Manager, Global Respiratory

• Zymeworks to acquire Theravance Biopharma and its Yupelri revefenacin inhalation solution

• Leyden Labs gets €40 million in financing for continued development of PanFlu antiviral nasal spray

• Pneumagen reorganizes as NorthLinks Bio to develop HEX17 mCBM nasal spray for the prevention of viral respiratory infections

• MannKind gets Breakthrough T1D grant to support trial of Afrezza insulin DPI in pediatric patients

More news . . .